- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07834242
Anaesthesia for Hip and Knee Arthroplasty (SPIGA) (SPIGA)
Spinal Versus General Anaesthesia for Hip and Knee Arthroplasty. The Randomised, Clinical, Multicentre SPIGA Trial
Beneficial and harmful effects of spinal versus general anaesthesia in patients undergoing hip and knee arthroplasty.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Effective and safe anaesthesia is fundamental to perioperative care. Hip and knee arthroplasty are among the most frequently performed surgical procedures worldwide and are typically performed under either spinal or general anaesthesia. However, high-quality comparative evidence regarding the benefits and harms of these anaesthetic techniques remains limited and inconclusive.
Both techniques are associated with short- and long-term risks, including postoperative nausea and vomiting, hypotension, nerve injury, acute kidney injury, and respiratory and cardiovascular complications. In addition, they may differentially modulate the surgical stress response, potentially influencing postoperative recovery and risk of complications.
Objective:
To compare the benefits and harms of spinal versus general anaesthesia in patients undergoing hip or knee replacement. We hypothesise that spinal anaesthesia results in better postoperative outcomes than general anaesthesia.
Intervention:
Patients undergoing elective primary hip or knee arthroplasty will be randomised to receive either spinal or general anaesthesia, with randomisation stratified by participating centre.
Design:
The SPIGA trial is an investigator-initiated, multicentre, randomised, superiority clinical trial. Participants will be randomly allocated at a 1:1 ratio using a central, computer-generated randomisation sequence. A total sample size of 3000 participants was determined using simulation-based methods to provide at least 90% power to detect a prespecified minimally clinically important difference, corresponding to an increase of one hospital-free day in at least 10% of participants at a two-sided significance level of 0.05.
Planned sub-studies
- Short-term perioperative outcomes (0-24h postoperatively)
- Stratified analysis of anaesthetic regimens
- Impact of preoperative clinical frailty
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Scheduled for elective primary elective hip or knee arthroplasty, including unicompartmental knee
Exclusion Criteria:
- Scheduled for elective primary hip or knee arthroplasty, including unicompartmental knee
- Age ≥ 18 years
- Unable to communicate in written and/or spoken Danish Contraindications against either spinal or general anaesthesia
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Spinal Anaesthesia
|
Spinal anaesthesia according to local practice, including optional sedation with sedative-hypnotic pharmacological agents |
|
Aktiver Komparator: General Anaesthesia
|
General anaesthesia according to local practice |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Hospital-free days within 30 days
Zeitfenster: Postoperative day 0-30
|
Defined as the number of days within the first 30 days following hip or knee arthroplasty surgery during which a participant is alive and not admitted to a hospital. |
Postoperative day 0-30
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Major complications
Zeitfenster: Postoperative day 0-30
|
A major complication is defined as a major intra- or postoperative adverse event occurring from the initiation of anaesthesia through 30 days postoperatively. |
Postoperative day 0-30
|
|
Quality of Recovery
Zeitfenster: 24 hours postoperatively
|
The Quality of Recovery-15 questionnaire (QoR-15) generates a composite score ranging from 0 to 150 across five domains (physical comfort, emotional state, physical independence, psychological support, and pain), with higher scores indicating better recovery. |
24 hours postoperatively
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient satisfaction with anaesthesia
Zeitfenster: 24 hours postoperatively
|
Assessed 24 hours postoperatively by asking patients to rate their satisfaction on a numeric rating scale (NRS) from 0-10, where 0 indicates not satisfied at all/completely dissatisfied and 10 indicates extremely satisfied/fully satisfied. |
24 hours postoperatively
|
|
Health-related quality of life (EQ5D5L-VAS)
Zeitfenster: Postoperative day 30
|
Evaluation of health-related quality of life using the EuroQol EQ5D5L- VAS questionnaire that adresses mobility, self-care, usual activities, pain/discomfort, anxiety/depression. The VAS is a vertical visual analogue score of self-rated health (EQ-VAS, 0 = "The worst health you can imagine" and 100 = "The best health you can imagine"). |
Postoperative day 30
|
|
Number of unplanned hospital-visits
Zeitfenster: Postoperative day 0-30
|
Defined as the number of any unplanned contact with the emergency department, outpatient clinic, or other hospital department. |
Postoperative day 0-30
|
|
Willingness to repeat the type of anaesthesia
Zeitfenster: 24 hours postoperatively
|
Assessed at 24 hours postoperatively by asking participants whether they would choose the same type of anaesthesia again in case of future surgery. |
24 hours postoperatively
|
|
Day-case discharge
Zeitfenster: Postoperative day 0
|
Number of patients assessed as eligible for day-case surgery being discharged on the day of surgery. |
Postoperative day 0
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- EMN-2026-05830
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data will be published anonymised in accordance with ICMJE (International Committee of Medical Journal Editors) guidelines.
IPD-Sharing-Zeitrahmen
The study protocol and statistical analysis plan will be available after they have been published.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .